As a consequence, Centinel Spine now has exclusive distribution rights to market Stalif TT products in all markets and countries globally. Centinel Spine expects to see increased revenue from this technology as early as first quarter of 2009.
John Viscogliosi, chairman and CEO of Centinel Spine, said: “The addition of the Stalif TT system to our product portfolio continues our winning formula of no profile stand alone interbody fusion technologies. It allows the company to benefit from the strengths of the Stalif TT technology in the form of tried and true proven scientific and clinical outcomes.
“With our improved and rapidly expanding distribution channels the Stalif TT will allow Centinel to significantly increase revenue while benefiting patients throughout the US.”